We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

MAST GROUP

Mast Group is an independent manufacturer and supplier of diagnostic products for clinical, industrial and veterinary... read more Featured Products: More products

Download Mobile App





Mast Group Introduces New MAST CARBA PAcE for Rapid Carbapenemase Detection

By LabMedica International staff writers
Posted on 21 Nov 2019
Print article
Image: MAST® CARBA PAcE (Photo courtesy of Mast Group Ltd.)
Image: MAST® CARBA PAcE (Photo courtesy of Mast Group Ltd.)
Mast Group Ltd. (Liverpool, UK) was amongst the 4,500 exhibitors from 70 countries that presented their products and services at the MEDICA 2019 Trade Fair held in Düsseldorf, Germany from 18-21st November. MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. MEDICA provides the medical device industry with a central market for innovative products and systems that result in an important contribution to the efficiency and quality of patient care. The combination of product shows with international congresses, forums, as well as expert workshops, and the exchange of professional views make MEDICA a meeting point for international professionals from various fields in the medical sector.

Mast is a manufacturer and supplier of diagnostic products for clinical, industrial and veterinary testing. The company manufactures microbiology and molecular biology products, as well as other infectious disease and autoimmune diagnostics, using a variety of technologies. At the 2019 edition of MEDICA, Mast introduced the new MAST CARBA PAcE for rapid carbapenemase detection in Pseudomonas spp., Acinetobacter spp. and Enterobacterales.

The company’s MAST ASSURE and CRYOBANK range also featured on the booth this year alongside its extensive range of MASTDISCS for antimicrobial susceptibility and resistance marker testing. MAST ASSURE’s extensive range contains both polyvalent and monovalent diagnostic antisera for the identification of Salmonella spp according to the expression of somatic antigens. Bacterial serotype can be determined by both slide agglutination and test tube agglutination methods.

The company’s MASTDISCS AST is available as an extensive range of antibiotic susceptibility test discs. Mast also offers an extensive range of MASTDISCS Combi antibiotic resistance detection sets for identification and differentiation of enzyme types using a combination disc technology, incorporating specific inhibitors to accurately detect extended spectrum ß-lactamase (ESßL), AmpC cephalosporinase, Metallo ß-lactamase (MBL) including VIM, IMP and NDM Klebsiella pneumoniae carbapenemase (KPC) and OXA-48 like carbapenemases.

Related Links:
Mast Group Ltd.

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.